FireEye, Inc. (FEYE), Impax Laboratories, Inc. (IPXL) Stock Eyes Ahead of Earnings

Impax Labs

Burning Stock on the move: Impax Laboratories Inc. (NASDAQ:IPXL)

These analysts and investment firms use various valuation methods to decide a price target for a stock.

Piper Jaffray Downgrade its coverage for Impax Laboratories Inc.

Impax Laboratories, Inc. (NASDAQ:IPXL) yearly performance is -73.78% and net profit margin is -57.30%.

For the Current Quarter, the growth estimate for Impax Laboratories -60.5%, while for the Next Quarter the stock growth estimate is 0%. The stock dropped -36.14% beyond one week and declined -33.58% during previous one month session. Furthermore on Dec-28-17 the stock was "Initiated" by Janney as Neutral at $15. RBC Capital Markets reiterated a "hold" rating and set a $15.00 price objective on shares of Impax Laboratories in a research note on Tuesday, January 3rd. (NASDAQ:IPXL) may hit a high of $20.

(NASDAQ:IPXL) reported its EPS in the last quarter as $0.16/Share lagging the analyst estimate of $0.16/Share by the difference of $0. According to 14 analysts, Price Target for Impax Laboratories Inc. However brokerage recommendations suggests an ABR of 3.11 based on calls of 9 experts, where 1 brokers polls the stock a Strong Buy, 0 suggest the stock a Buy, 6 suggest Hold, 1 are rating the stock as Sell while 1 as Strong Sell. Movements above 70 are interpreted as indicating overbought conditions; conversely moves underneath 30 notify oversold conditions. The stock opened for trading at $8.35 and hit $9.5 on the upside, eventually ending the session at $9.1, with a gain of 8.33% or 0.7 points. (NASDAQ:IPXL) reported its Actual EPS of $0.16/share. According to these analysts, the Low Revenue Estimate for Impax Laboratories 179.8 Million and the High Revenue Estimate is 254 Million. (NASDAQ:IPXL) which led to swings in the share price. For the current quarter the stock has lowest EPS estimates of $0.07 and high estimate of $0.47. The Next Year EPS growth is 36.3%, Long term annual growth estimate of 14%, Annual EPS growth past 5 years of -5.34 percent.

The company's stock now has 811.6 Million in market capitalization.

The Relative Volume of the company is 4.93 and Average Volume (3 months) is 1.56 million.

Analysts are weighing in on oilfield services provider Weatherford International Plc (NYSE:WFT), as well as biotech stocks Impax Laboratories Inc (NASDAQ:IPXL) and Cytokinetics, Inc. Beta value of the stock is marked at 1.23. The stock has a 50 day moving average of $12.75 and a 200-day moving average of $17.38. The Moving Average SMA50 is -35.92% while SMA200 is -61.25%.

In case of Revenue Estimates, 11 analysts have provided their consensus Average Revenue Estimates for Impax Laboratories 207.57 Million. The Return on Equity (ROE) value stands at -51.4%.

While looking at the Stock's Performance, Impax Laboratories Inc. now shows a Weekly Performance of -36.14%, where Monthly Performance is -33.58%, Quarterly performance is -33.33%, 6 Months performance is -62.13% and yearly performance percentage is -73.78%.

This year, the company showed a disappointed -21.6 percent of growth. There was a stock increase by 3.3 percent. During the same period in the previous year, the firm posted $0.62 earnings per share. The stock Fell -64.91 percent over the past six months.

Dividend Stock Updates: Staples, Inc. (SPLS)
Chicago Bears will release quarterback Jay Cutler